Zelira Therapeutics Limited (ASX:ZLD)

Oludare Odumosu
Global CEO
Market Cap (AUD): 9.29M
Sector: Health Care
Last Trade (AUD): 0.97 +0 (+0%)
Tab Bar

1. About

Zelira Therapeutics Limited (ASX:ZLD) (formerly Zelda Therapeutics) is a leading global therapeutic medicinal cannabis company with access to the worlds largest and fastest growing cannabis markets. 

Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focussed on developing branded cannabis products for the treatment of a variety of medical conditions.

Zelira has launched two proprietary formulations under the HOPE brand for Autism in multiple US-states with plans to expand into global markets in 2020. 

The Company is also undertaking:

  • Human clinical trials focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
  • Pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

 

The Company conducts this work in partnership with world-leading researchers and organisations including Curtin University in Perth, Western Australia; the Telethon Kids Institute; the University of Western Australia, in Perth; St. Vincents Hospital in Melbourne, Australia; and the Childrens Hospital of Philadelphia (CHOP) in the United States.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA Pharms EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.

The Company has developed two proprietary formulations (HOPE) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products. The company also has a partnership with Ethicann for the development of a proprietary product, CAN-001, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV), which occurs in approximately 80% of the new 23.6 million cases of cancer annually worldwide.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk